ArticleCell death & disease2025
Cellular adaptations impact the biological activity of naphthalene diimide G-quadruplex ligands in ALT-positive osteosarcoma cells.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Two dipeptide repeat proteins are produced from mammalian telomeric RNA previously thought to be a long non-coding RNA.RNA biology · 2026Review
- DNA damaging properties of G-quadruplex ligand QN-302 are potentiated by the DNA repair inhibitor Olaparib and mitigated by the molecular helicase PhpC.Genome biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Telomeric G-quadruplexes (G4s) represent intriguing targets for tumours characterized by the Alternative Lengthening of Telomere (ALT) mechanism. Here we have investigated the effects of two naphthalene diimide (NDI)-based G4 interacting agents (NMe2 and QN-302) in a pair of ALT-positive human osteosarcoma (U-2 OS and Saos-2) cell lines. Both NDIs displayed marked cell growth inhibitory activity associated with the induction of telomere dysfunctions. Moreover, NDI-treated cells were characterized by perturbations at the mitochondrial level as suggested by an increase in the production of reactive oxygen species, the occurrence of changes in mitochondria density and morphology. However, upon initial inhibition of cell growth, U-2 OS cells withstood ligand-induced stress compared to Saos-2 cells. This ability was in part sustained, in a ligand-dependent manner, by the lack of ALT activity inhibition, as indicated by the levels of telomeric C-circle DNA and of Bloom helicase, a member of the RecQ family of helicases. Moreover, marked basal antioxidant capacity, together with the capability to mount an antioxidant response that is in part mediated by the nuclear factor erythroid 2-related factor, has endowed U-2 OS cells with the ability to adapt to NDI exposure. Our data indicate that NDIs rapidly affect the growth of ALT cancer cells by interfering with telomere and mitochondria homeostasis and suggest that small molecule-mediated stabilization of G4s may be a promising therapeutic strategy in ALT-positive tumors. Nonetheless, depending on the individual NDI and the cell's genetic background, cellular adjustment mechanisms may become activated. This, in turn may impinge on the biological activity of G4 interacting agents. Deciphering these mechanisms and the associated molecular determinants will help accelerating the development of G4-based therapeutic interventions in ALT tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.